Research and Markets: Xenical (Obesity) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/vnvd6j/xenical_obesity) has announced the addition of the "Xenical (Obesity) - Forecast and Market Analysis to 2022" report to their offering.

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Xenical is on patent until 2018 in the US and belongs to a class of drugs known as lipase inhibitors which act on the lipase enzyme to inhibit the absorption of fat in the diet. Dietary fat that is not broken down cannot be absorbed and is eliminated, resulting in a caloric deficit for a positive effect on weight control. Xenical is the only anti-obesity drug approved by the FDA for long-term usage (up to one year) for adults and children age 12 and older.

Scope

- Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Xenical including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Xenical for the top eight countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Key Topics Covered:

List of Tables

List of Figures

Introduction

Disease Overview

Disease Management

Competitive Assessment

Xenical (orlistat)

Appendix

For more information visit http://www.researchandmarkets.com/research/vnvd6j/xenical_obesity.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals